DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Bliss GVS Pharma Limited — Board Meeting Intimation

NSE 1 hr ago·22 Oct 2026, 2:49 pm

Bliss GVS Pharma

Bliss GVS Pharma has announced that its board will meet on October 29, 2026, to review and approve the company's unaudited financial results for the first half of the fiscal year ending September 2026. This routine corporate action is a standard procedure for listed companies to disclose their interim performance to shareholders and the stock market.

For investors, this announcement is a key milestone as it provides an early glimpse into the company's operational health and financial trajectory. The results will reveal how the firm is performing against its peers and whether its business strategy is yielding the expected growth in the current market conditions.

Investors should watch for the specific details of the earnings report, particularly the growth in revenue and profit margins. The market will likely react to the guidance provided by the management regarding future performance, which will offer further context on the company's outlook for the remainder of the year.